Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, China.
Suzhou Medical College of Soochow University, Suzhou, China.
CNS Neurosci Ther. 2023 Sep;29(9):2445-2456. doi: 10.1111/cns.14240. Epub 2023 May 14.
Remote ischemic conditioning (RIC) is a remote, transient, and noninvasive procedure providing temporary ischemia and reperfusion. However, there is no comprehensive literature investigating the efficacy and safety of RIC for the treatment of acute ischemic stroke. In the present study, we performed a comprehensive meta-analysis of the available studies.
MEDLINE, Embase, the Cochrane Library database (CENTRAL), and ClinicalTrials.gov were searched before Sep 7, 2022. The data were analyzed using Review Manager 5.4.1 software, Stata version 16.0 software, and R 4.2.0 software. Odds ratio (OR), mean difference (MD), and corresponding 95% CIs were pooled using fixed-effects meta-analysis.
We pooled 6392 patients from 17 randomized controlled trials. Chronic RIC could reduce the recurrence of ischemic stroke at the endpoints (OR 0.67, 95% CI [0.51, 0.87]). RIC could also improve the prognosis of patients at 90 days as assessed by mRS score (mRS 0-1: OR 1.29, 95% CI [1.09, 1.52]; mRS 0-2: OR 1.22, 95% CI [1.01, 1.48]) and at the endpoints assessed by NIHSS score (MD -0.99, 95% CI [-1.45, -0.53]). RIC would not cause additional adverse events such as death (p = 0.72), intracerebral hemorrhage events (p = 0.69), pneumonia (p = 0.75), and TIA (p = 0.24) but would inevitably cause RIC-related adverse events (OR 26.79, 95% CI [12.08, 59.38]).
RIC could reduce the stroke recurrence and improve patients' prognosis. Intervention on bilateral upper limbs, 5 cycles, and a length of 50 min in each intervention might be an optimal protocol for RIC at present. RIC could be an effective therapy for patients not eligible for reperfusion therapy. RIC would not cause other adverse events except for relatively benign RIC-related adverse events.
远程缺血预处理(RIC)是一种远程、短暂、非侵入性的程序,可提供短暂的缺血再灌注。然而,目前尚无综合文献调查 RIC 治疗急性缺血性卒中的疗效和安全性。在本研究中,我们对现有研究进行了综合荟萃分析。
在 2022 年 9 月 7 日之前,我们检索了 MEDLINE、Embase、Cochrane 图书馆数据库(CENTRAL)和 ClinicalTrials.gov。使用 Review Manager 5.4.1 软件、Stata 版本 16.0 软件和 R 4.2.0 软件对数据进行分析。使用固定效应荟萃分析合并比值比(OR)、均数差(MD)和相应的 95%置信区间(CI)。
我们从 17 项随机对照试验中汇总了 6392 名患者。慢性 RIC 可降低终点时的缺血性卒中复发率(OR 0.67,95%CI [0.51,0.87])。RIC 还可以改善 90 天时 mRS 评分评估的患者预后(mRS 0-1:OR 1.29,95%CI [1.09,1.52];mRS 0-2:OR 1.22,95%CI [1.01,1.48])和终点时 NIHSS 评分评估的预后(MD-0.99,95%CI [-1.45,-0.53])。RIC 不会引起额外的不良事件,如死亡(p=0.72)、脑出血事件(p=0.69)、肺炎(p=0.75)和 TIA(p=0.24),但不可避免地会引起与 RIC 相关的不良事件(OR 26.79,95%CI [12.08,59.38])。
RIC 可降低卒中复发率,改善患者预后。目前,双侧上肢、5 个循环、每个干预 50 分钟的干预可能是 RIC 的最佳方案。RIC 可能是一种对不适合再灌注治疗的患者有效的治疗方法。除了相对良性的 RIC 相关不良事件外,RIC 不会引起其他不良事件。